{"gene":"ABHD17A","run_date":"2026-06-09T22:02:37","timeline":{"discoveries":[{"year":2015,"finding":"ABHD17 proteins (including ABHD17A) function as novel protein depalmitoylases that accelerate palmitate turnover on N-Ras and PSD-95. ABHD17A catalytic activity is required for N-Ras depalmitoylation and re-localization from the plasma membrane to internal cellular membranes. APT1/APT2 inhibition did not affect N-Ras or PSD-95 palmitate turnover, establishing ABHD17 enzymes as distinct, non-redundant depalmitoylases identified via activity-based profiling of serine hydrolases.","method":"Dual pulse-chase comparing palmitate and protein half-lives; activity-based protein profiling; shRNA knockdown; small-molecule inhibition (Palmostatin B); subcellular localization imaging","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (pulse-chase, activity profiling, KD, inhibitor, localization), replicated across substrates, foundational study","pmids":["26701913"],"is_preprint":false},{"year":2016,"finding":"ABHD17A, ABHD17B, and ABHD17C are the physiological depalmitoylating enzymes for PSD-95 in neurons. ABHD17A localizes to recycling endosomes, the dendritic plasma membrane, and the synaptic fraction. Expression of ABHD17 in neurons selectively reduced PSD-95 palmitoylation and synaptic clustering of PSD-95 and AMPA receptors. Inhibition of ABHD17 expression dramatically delayed the kinetics of PSD-95 depalmitoylation as quantified by the APEGS method.","method":"Heterologous cell depalmitoylation assay; APEGS quantitative palmitoylation assay; neuronal expression/knockdown; immunofluorescence localization; synaptic fractionation","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (biochemical assay, quantitative APEGS, KD, localization, functional synaptic readout) in a single rigorous study","pmids":["27307232"],"is_preprint":false},{"year":2017,"finding":"ABHD17A-C depalmitoylating enzymes control dynamic palmitoylation of MAP6/STOP protein, regulating its shuttling between membranes and microtubules and its retention in axons. ABHD17-mediated depalmitoylation is required for MAP6-dependent microtubule stabilization and axon maturation.","method":"Live imaging; neuronal KD/OE; palmitoylation biochemical assays; axonal localization experiments","journal":"Neuron","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct loss-of-function with defined cellular phenotype (axon maturation, MAP6 localization), single lab, multiple methods","pmids":["28521134"],"is_preprint":false},{"year":2019,"finding":"ABHD17A acts as a depalmitoylase for TEAD transcription factors, contributing to TEAD destabilization and proteasomal degradation via E3 ubiquitin ligase CHIP when TEAD is depalmitoylated. TEAD depalmitoylation by ABHD17A (and APT2) is regulated by cell density in a Nf2/Merlin-dependent manner.","method":"Overexpression of ABHD17A; palmitoylation assays; cell density manipulation; proteasome inhibitor treatment; Nf2/Merlin knockdown","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional assays with defined molecular outcome (TEAD depalmitoylation, degradation), single lab, multiple methods","pmids":["31043565"],"is_preprint":false},{"year":2020,"finding":"ABHD17A deacylates the stress-regulated exon (STREX) domain of BK channels in a site-specific manner, inhibiting channel activity without affecting surface expression. ABHD17A has no effect on the S0-S1 domain of BK channels (which is deacylated by Lypla1), demonstrating that distinct S-acylated domains within the same polytopic transmembrane protein are regulated by different acyl protein thioesterases.","method":"Overexpression and knockdown of ABHD17A; acyl-biotin exchange assay; electrophysiology; surface biotinylation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional assay (electrophysiology + biochemical deacylation), site-specificity shown, single lab","pmids":["32913120"],"is_preprint":false},{"year":2021,"finding":"ABHD17A depalmitoylates the divergent C-terminal tail of CNAβ1 (a calcineurin isoform), reversing its palmitoylation-dependent plasma membrane and Golgi localization and thereby altering its substrate specificity and function at the PI4KA complex.","method":"Depalmitoylase overexpression; palmitoylation assays; subcellular localization imaging; hydrogen-deuterium exchange MS; substrate identification","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization and palmitoylation assays with functional consequence, multiple methods, single lab","pmids":["34663815"],"is_preprint":false},{"year":2023,"finding":"ABHD17A depalmitoylates NLRP3 at the LRR domain, counteracting ZDHHC5-mediated NLRP3 palmitoylation. A Crohn's disease-associated NLRP3 mutation was found to be associated with defective ABHD17A binding and hyper-palmitoylation, linking ABHD17A to inflammasome regulation.","method":"Silencing and overexpression; palmitoylation assays; co-immunoprecipitation; NLRP3 inflammasome activation assays (caspase-1, IL-1β, GSDMD); site-directed mutagenesis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Co-IP, palmitoylation assay, functional inflammasome readouts, mutagenesis, in vivo mouse data), single rigorous study","pmids":["38092000"],"is_preprint":false},{"year":2024,"finding":"ABHD17A is the depalmitoylating enzyme for Rap2b in colorectal cancer cells, removing palmitate from C176/C177, causing Rap2b relocation from the plasma membrane to the cytosol and inhibiting cell migration and invasion. PI3K signaling phosphorylates ABHD17A to modulate its depalmitoylase activity on Rap2b.","method":"ABHD17A overexpression/KD; palmitoylation assays; subcellular fractionation/localization; migration/invasion assays; pharmacological PI3K inhibition","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct depalmitoylation and localization assays with functional cell migration readout, single lab, multiple methods","pmids":["39277583"],"is_preprint":false},{"year":2024,"finding":"ABHD17A depalmitoylates SCAP, antagonizing ZDHHC3-mediated SCAP S-acylation at C264 and thereby modulating SCAP ubiquitination and cholesterol biosynthesis in hepatocellular carcinoma cells.","method":"Overexpression/KD; palmitoylation assays; ubiquitination assays; cholesterol biosynthesis measurement","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct depalmitoylation assay with defined functional output (SCAP ubiquitination, cholesterol), single lab, multiple methods","pmids":["39522165"],"is_preprint":false},{"year":2025,"finding":"ABHD17A (and ABHD17B, ABHD17C) are the acyl protein thioesterases responsible for NOD2 deacylation. Inhibiting ABHD17 increased plasma membrane localization of NOD2 and enhanced NOD2-dependent NF-κB activation and pro-inflammatory cytokine production, including for Crohn's disease-associated poorly-acylated NOD2 variants.","method":"RNA interference; small-molecule ABHD17 inhibitors; acyl-resin-assisted capture; confocal microscopy; immunoblotting; cytokine multiplex assays","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (RNAi, inhibitors, biochemical acylation capture, imaging, functional NF-κB/cytokine readout), single lab","pmids":["40054525"],"is_preprint":false},{"year":2025,"finding":"ABHD17A physically interacts with IFITM1 and, unexpectedly, increases IFITM1 S-palmitoylation (rather than removing it) by downregulating the depalmitoylase ABHD16A. This indirect mechanism counteracts ABHD16A-catalyzed palmitate removal from IFITM1, thereby enhancing IFITM1's antiviral activity.","method":"Co-immunoprecipitation; palmitoylation assays; overexpression/KD of ABHD17A and ABHD16A; antiviral functional assays","journal":"Biomolecules","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus palmitoylation biochemistry and functional antiviral readout, single lab, multiple methods","pmids":["40723864"],"is_preprint":false},{"year":2025,"finding":"ABHD17A's plasma membrane targeting and catalytic activity are governed by a palmitoylation code in its conserved N-terminal cysteine cluster (C10, C11, C14, C15, C18). Modifications at the middle region (C14, C15) are critical for PM targeting and catalytic activity, while front (C10, C11) and rear (C18) modifications influence endosomal routing. YXXØ-dependent endosomal sorting (disruption of L115A proximal motif) redirects ABHD17A to autophagosomes and decreases surface abundance. This palmitoylation code mechanism is conserved in ABHD17B and ABHD17C.","method":"Alanine scanning mutagenesis; confocal microscopy; biochemical acylation assays; ABHD17A substrate depalmitoylation assays","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis, imaging, and biochemical assays establishing mechanism, single lab, single study","pmids":["41155484"],"is_preprint":false},{"year":2025,"finding":"ABHD17A is identified as one of the deacylating enzymes regulating the dynamic fatty acylation cycle of GSDMA, controlling GSDMA-mediated pyroptosis.","method":"Identification via biochemical deacylation assay; functional pyroptosis readout","journal":"ACS chemical biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single study, limited mechanistic detail in abstract about specific method used for ABHD17A's role","pmids":["41972293"],"is_preprint":false},{"year":2026,"finding":"ABHD17A depalmitoylates METTL3 at cysteine 376, reversing ZDHHC24-mediated palmitoylation. This depalmitoylation disrupts METTL3 condensate formation near ribosomes and promotes chaperone-mediated autophagy of METTL3, reducing its stability. A small molecule (Isoborneol) that disrupts METTL3–ABHD17A interaction enhances METTL3 palmitoylation and alleviates osteoarthritis in vivo.","method":"Palmitoylation assays; co-immunoprecipitation; condensate imaging; KO/OE in cells and mice; OA mouse models; AI-guided small-molecule screening","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct depalmitoylation assay, Co-IP, in vivo phenotype, multiple methods; single lab","pmids":["41719123"],"is_preprint":false}],"current_model":"ABHD17A is a membrane-anchored serine hydrolase/depalmitoylase that removes S-palmitoyl modifications from a growing list of substrates—including N-Ras, PSD-95, MAP6, TEAD, BK channels, CNAβ1, NLRP3, Rap2b, SCAP, NOD2, GSDMA, and METTL3—regulating their membrane association, subcellular localization, protein–protein interactions, and downstream signaling; ABHD17A's own depalmitoylase activity and plasma membrane targeting are controlled by a palmitoylation code in its N-terminal cysteine cluster and by YXXØ-dependent endosomal sorting, and it can also indirectly increase substrate palmitoylation by downregulating competing depalmitoylases such as ABHD16A."},"narrative":{"mechanistic_narrative":"ABHD17A is a membrane-anchored serine hydrolase that acts as a protein depalmitoylase, accelerating the turnover of S-palmitoyl modifications on substrate proteins and thereby controlling their membrane association, subcellular localization, and downstream signaling [PMID:26701913]. It was identified by activity-based serine-hydrolase profiling as a non-redundant depalmitoylase—distinct from APT1/APT2—that drives palmitate turnover on N-Ras and PSD-95, with its catalytic activity required to relocate N-Ras from the plasma membrane to internal membranes [PMID:26701913]; in neurons it depalmitoylates PSD-95 from recycling endosomes and the synaptic compartment to regulate synaptic PSD-95 and AMPA receptor clustering [PMID:27307232]. Its substrate range is broad, spanning cytoskeletal and signaling proteins such as MAP6 in axon maturation [PMID:28521134], TEAD transcription factors whose depalmitoylation promotes CHIP-mediated degradation in a density/Nf2-dependent manner [PMID:31043565], site-specific deacylation of the BK channel STREX domain [PMID:32913120], and CNAβ1 calcineurin [PMID:34663815]. A recurring theme is direct antagonism of ZDHHC palmitoyltransferases at defined cysteines: ABHD17A counters ZDHHC5 on NLRP3, ZDHHC3 on SCAP, and ZDHHC24 on METTL3, thereby tuning inflammasome activity [PMID:38092000], cholesterol biosynthesis [PMID:39522165], and METTL3 condensate formation and stability [PMID:41719123]. Through these activities it modulates innate immune signaling—NLRP3 and NOD2 deacylation linking it to Crohn's disease-associated variants [PMID:38092000, PMID:40054525]—as well as cancer cell migration via Rap2b [PMID:39277583]. ABHD17A's own plasma-membrane targeting and catalytic activity are governed by a palmitoylation code in its N-terminal cysteine cluster and by YXXØ-dependent endosomal sorting [PMID:41155484], and it can paradoxically raise substrate palmitoylation indirectly by downregulating the competing depalmitoylase ABHD16A [PMID:40723864].","teleology":[{"year":2015,"claim":"Established that ABHD17 enzymes are a previously unrecognized class of protein depalmitoylase, resolving how palmitate turnover proceeds on N-Ras and PSD-95 independently of APT1/APT2.","evidence":"Dual pulse-chase of palmitate vs protein half-life, activity-based protein profiling, shRNA knockdown, Palmostatin B inhibition and localization imaging","pmids":["26701913"],"confidence":"High","gaps":["Catalytic mechanism and structural basis of substrate selection not defined","Endogenous substrate repertoire beyond N-Ras/PSD-95 unknown at this stage"]},{"year":2016,"claim":"Showed ABHD17A is a physiological PSD-95 depalmitoylase in neurons, linking its activity to synaptic receptor clustering and defining its endosomal/synaptic localization.","evidence":"Heterologous depalmitoylation assay, quantitative APEGS palmitoylation measurement, neuronal expression/knockdown, immunofluorescence and synaptic fractionation","pmids":["27307232"],"confidence":"High","gaps":["Relative contribution of ABHD17A vs ABHD17B/C in vivo not separated","Mechanism targeting the enzyme to recycling endosomes not defined"]},{"year":2017,"claim":"Extended substrate scope to cytoskeleton-associated MAP6, connecting depalmitoylation to microtubule stabilization and axon maturation.","evidence":"Live imaging, neuronal knockdown/overexpression, palmitoylation biochemistry, axonal localization assays","pmids":["28521134"],"confidence":"Medium","gaps":["Direct enzyme-substrate interaction not biochemically isolated","ABHD17 isoform-specific roles not resolved"]},{"year":2019,"claim":"Connected ABHD17A depalmitoylation to transcription-factor turnover, showing TEAD depalmitoylation routes it to CHIP-mediated proteasomal degradation under density/Nf2 control.","evidence":"ABHD17A overexpression, palmitoylation assays, cell-density manipulation, proteasome inhibition, Nf2/Merlin knockdown","pmids":["31043565"],"confidence":"Medium","gaps":["Endogenous ABHD17A loss-of-function effect on TEAD not established","Shared role with APT2 not deconvolved"]},{"year":2020,"claim":"Demonstrated site-specificity by showing ABHD17A deacylates only the STREX domain of BK channels (not S0-S1), establishing that distinct acylated domains of one protein are served by different thioesterases.","evidence":"Overexpression/knockdown, acyl-biotin exchange, electrophysiology, surface biotinylation","pmids":["32913120"],"confidence":"Medium","gaps":["Structural basis for domain selectivity unknown","Single-lab finding"]},{"year":2021,"claim":"Showed ABHD17A depalmitoylates CNAβ1 calcineurin to reverse its membrane/Golgi localization and alter its substrate specificity.","evidence":"Depalmitoylase overexpression, palmitoylation assays, localization imaging, HDX-MS substrate analysis","pmids":["34663815"],"confidence":"Medium","gaps":["Physiological setting and endogenous regulation not established"]},{"year":2023,"claim":"Defined ABHD17A as a direct ZDHHC5 antagonist on NLRP3 and tied it to inflammasome control and a Crohn's disease-associated NLRP3 variant with defective ABHD17A binding.","evidence":"Silencing/overexpression, palmitoylation assays, co-immunoprecipitation, inflammasome readouts (caspase-1, IL-1β, GSDMD), mutagenesis, in vivo mouse data","pmids":["38092000"],"confidence":"High","gaps":["Determinants of NLRP3-ABHD17A binding interface not mapped","Causal disease contribution beyond association not established"]},{"year":2024,"claim":"Identified ABHD17A as the Rap2b depalmitoylase regulated by PI3K-mediated phosphorylation, linking its activity to colorectal cancer cell migration and invasion.","evidence":"Overexpression/knockdown, palmitoylation assays, fractionation/localization, migration/invasion assays, PI3K inhibition","pmids":["39277583"],"confidence":"Medium","gaps":["Phosphosite(s) on ABHD17A controlling activity not mapped","In vivo tumor relevance not established"]},{"year":2024,"claim":"Showed ABHD17A antagonizes ZDHHC3 acylation of SCAP at C264 to modulate SCAP ubiquitination and cholesterol biosynthesis.","evidence":"Overexpression/knockdown, palmitoylation assays, ubiquitination assays, cholesterol measurement in hepatocellular carcinoma cells","pmids":["39522165"],"confidence":"Medium","gaps":["Direct vs indirect effect on SCAP ubiquitination not fully separated","Single-lab, single-cell-context finding"]},{"year":2025,"claim":"Established ABHD17 enzymes as the NOD2 deacylases controlling its membrane localization and NF-κB output, including for Crohn's-associated poorly-acylated variants.","evidence":"RNAi, small-molecule ABHD17 inhibitors, acyl-resin-assisted capture, confocal microscopy, cytokine multiplex assays","pmids":["40054525"],"confidence":"Medium","gaps":["ABHD17A-specific contribution vs ABHD17B/C not isolated","Direct NOD2 binding not demonstrated"]},{"year":2025,"claim":"Revealed an indirect, non-catalytic mode in which ABHD17A increases IFITM1 palmitoylation by downregulating the competing depalmitoylase ABHD16A, enhancing antiviral activity.","evidence":"Co-immunoprecipitation, palmitoylation assays, overexpression/knockdown of ABHD17A and ABHD16A, antiviral functional assays","pmids":["40723864"],"confidence":"Medium","gaps":["Mechanism by which ABHD17A downregulates ABHD16A unknown","Direct vs indirect IFITM1 effect not fully resolved"]},{"year":2025,"claim":"Defined the regulatory logic of ABHD17A itself: an N-terminal cysteine palmitoylation code and YXXØ endosomal sorting motif govern its PM targeting, catalytic activity, and trafficking.","evidence":"Alanine-scanning mutagenesis, confocal microscopy, acylation assays, substrate depalmitoylation assays","pmids":["41155484"],"confidence":"Medium","gaps":["Enzymes writing/erasing the ABHD17A code not identified","Dynamics of the code under physiological signaling unknown"]},{"year":2025,"claim":"Implicated ABHD17A among the deacylases regulating GSDMA fatty-acylation cycling and pyroptosis.","evidence":"Biochemical deacylation assay and pyroptosis functional readout","pmids":["41972293"],"confidence":"Low","gaps":["Limited mechanistic detail on ABHD17A's specific role","ABHD17A-specific loss-of-function not isolated"]},{"year":2026,"claim":"Showed ABHD17A depalmitoylates METTL3 at C376 to disrupt its condensates and promote chaperone-mediated autophagy, with a small molecule blocking the interaction alleviating osteoarthritis.","evidence":"Palmitoylation assays, co-IP, condensate imaging, KO/OE in cells and mice, OA models, AI-guided small-molecule screening","pmids":["41719123"],"confidence":"Medium","gaps":["Structural basis of METTL3-ABHD17A binding not defined","Generalizability beyond osteoarthritis context unknown"]},{"year":null,"claim":"How ABHD17A achieves its broad yet site-specific substrate selectivity, and how its activity is dynamically regulated across tissues by phosphorylation and its own palmitoylation code, remains unresolved.","evidence":"No structural or systematic substrate-determinant study present in the corpus","pmids":[],"confidence":"Low","gaps":["No structure of ABHD17A or enzyme-substrate complex","Determinants distinguishing direct depalmitoylation from indirect ABHD16A-mediated effects not generalized","Isoform-specific (A vs B vs C) division of labor not systematically defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,4,6,7,8,13]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,4]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,11]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[1,11]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,1,6,8,13]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,9]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,7]}],"complexes":[],"partners":["NLRP3","NOD2","RAP2B","SCAP","TEAD","METTL3","IFITM1","ABHD16A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q96GS6","full_name":"Alpha/beta hydrolase domain-containing protein 17A","aliases":[],"length_aa":310,"mass_kda":34.0,"function":"Hydrolyzes fatty acids from S-acylated cysteine residues in proteins (PubMed:26701913). Has depalmitoylating activity towards NRAS (PubMed:26701913). Has depalmitoylating activity towards DLG4/PSD95 (PubMed:26701913). May have depalmitoylating activity towards MAP6 (By similarity)","subcellular_location":"Cell membrane; Endosome membrane; Cell projection, dendritic spine; Postsynaptic density membrane","url":"https://www.uniprot.org/uniprotkb/Q96GS6/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ABHD17A","classification":"Not Classified","n_dependent_lines":196,"n_total_lines":1208,"dependency_fraction":0.16225165562913907},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ABHD17A","total_profiled":1310},"omim":[{"mim_id":"617944","title":"ABHYDROLASE DOMAIN-CONTAINING PROTEIN 17C, DEPALMITOYLASE; ABHD17C","url":"https://www.omim.org/entry/617944"},{"mim_id":"617943","title":"ABHYDROLASE DOMAIN-CONTAINING PROTEIN 17B, DEPALMITOYLASE; ABHD17B","url":"https://www.omim.org/entry/617943"},{"mim_id":"617942","title":"ABHYDROLASE DOMAIN-CONTAINING PROTEIN 17A, DEPALMITOYLASE; ABHD17A","url":"https://www.omim.org/entry/617942"},{"mim_id":"164790","title":"NRAS PROTOONCOGENE, GTPase; NRAS","url":"https://www.omim.org/entry/164790"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Nuclear speckles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":203.3}],"url":"https://www.proteinatlas.org/search/ABHD17A"},"hgnc":{"alias_symbol":["MGC5244"],"prev_symbol":["C19orf27","FAM108A1"]},"alphafold":{"accession":"Q96GS6","domains":[{"cath_id":"3.40.50.1820","chopping":"65-307","consensus_level":"medium","plddt":96.7056,"start":65,"end":307}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96GS6","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96GS6-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96GS6-F1-predicted_aligned_error_v6.png","plddt_mean":88.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ABHD17A","jax_strain_url":"https://www.jax.org/strain/search?query=ABHD17A"},"sequence":{"accession":"Q96GS6","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96GS6.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96GS6/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96GS6"}},"corpus_meta":[{"pmid":"26701913","id":"PMC_26701913","title":"ABHD17 proteins are novel protein depalmitoylases that regulate N-Ras palmitate turnover and subcellular localization.","date":"2015","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/26701913","citation_count":283,"is_preprint":false},{"pmid":"27307232","id":"PMC_27307232","title":"Identification of PSD-95 Depalmitoylating Enzymes.","date":"2016","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27307232","citation_count":193,"is_preprint":false},{"pmid":"36018061","id":"PMC_36018061","title":"Protein palmitoylation in cancer: molecular functions and therapeutic potential.","date":"2022","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36018061","citation_count":153,"is_preprint":false},{"pmid":"38092000","id":"PMC_38092000","title":"ZDHHC5-mediated NLRP3 palmitoylation promotes NLRP3-NEK7 interaction and inflammasome activation.","date":"2023","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/38092000","citation_count":122,"is_preprint":false},{"pmid":"28521134","id":"PMC_28521134","title":"Dynamic Palmitoylation Targets MAP6 to the Axon to Promote Microtubule Stabilization during Neuronal Polarization.","date":"2017","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/28521134","citation_count":94,"is_preprint":false},{"pmid":"28485685","id":"PMC_28485685","title":"Protein palmitoylation: Palmitoyltransferases and their specificity.","date":"2017","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/28485685","citation_count":79,"is_preprint":false},{"pmid":"31043565","id":"PMC_31043565","title":"Cell contact and Nf2/Merlin-dependent regulation of TEAD palmitoylation and activity.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31043565","citation_count":77,"is_preprint":false},{"pmid":"28630138","id":"PMC_28630138","title":"Targeting the Ras palmitoylation/depalmitoylation cycle in cancer.","date":"2017","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/28630138","citation_count":66,"is_preprint":false},{"pmid":"34663815","id":"PMC_34663815","title":"Palmitoylation targets the calcineurin phosphatase to the phosphatidylinositol 4-kinase complex at the plasma membrane.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34663815","citation_count":42,"is_preprint":false},{"pmid":"39522165","id":"PMC_39522165","title":"ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39522165","citation_count":29,"is_preprint":false},{"pmid":"19005066","id":"PMC_19005066","title":"Molecular correlates of laminar differences in the macaque dorsal lateral geniculate nucleus.","date":"2008","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19005066","citation_count":18,"is_preprint":false},{"pmid":"32913120","id":"PMC_32913120","title":"Site-specific deacylation by ABHD17a controls BK channel splice variant activity.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32913120","citation_count":17,"is_preprint":false},{"pmid":"39277583","id":"PMC_39277583","title":"Inhibiting S-palmitoylation arrests metastasis by relocating Rap2b from plasma membrane in colorectal cancer.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/39277583","citation_count":12,"is_preprint":false},{"pmid":"38464509","id":"PMC_38464509","title":"CD8+ T and NK cells characterized by upregulation of NPEPPS and ABHD17A are associated with the co-occurrence of type 2 diabetes and coronary artery disease.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38464509","citation_count":8,"is_preprint":false},{"pmid":"40842862","id":"PMC_40842862","title":"Integrated multi-omics characterization across clinically relevant subgroups of long COVID.","date":"2024","source":"National science review","url":"https://pubmed.ncbi.nlm.nih.gov/40842862","citation_count":8,"is_preprint":false},{"pmid":"40054525","id":"PMC_40054525","title":"Attenuating ABHD17 Isoforms Augments the S-acylation and Function of NOD2 and a Subset of Crohn's Disease-associated NOD2 Variants.","date":"2025","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/40054525","citation_count":7,"is_preprint":false},{"pmid":"40723864","id":"PMC_40723864","title":"The Unconventional Role of ABHD17A in Increasing the S-Palmitoylation and Antiviral Activity of IFITM1 by Downregulating ABHD16A.","date":"2025","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/40723864","citation_count":6,"is_preprint":false},{"pmid":"38187608","id":"PMC_38187608","title":"Attenuating ABHD17 isoforms augments the S-acylation and function of NOD2 and a subset of Crohn's disease-associated NOD2 variants.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38187608","citation_count":6,"is_preprint":false},{"pmid":"39536392","id":"PMC_39536392","title":"Multi-omic characteristics of longitudinal immune profiling after breakthrough infections caused by Omicron BA.5 sublineages.","date":"2024","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/39536392","citation_count":4,"is_preprint":false},{"pmid":"41155484","id":"PMC_41155484","title":"Palmitoylation Code and Endosomal Sorting Regulate ABHD17A Plasma Membrane Targeting and Activity.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41155484","citation_count":1,"is_preprint":false},{"pmid":"41719123","id":"PMC_41719123","title":"Small-molecule enhancement of METTL3 S-palmitoylation as a therapeutic strategy for osteoarthritis.","date":"2026","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/41719123","citation_count":0,"is_preprint":false},{"pmid":"41972293","id":"PMC_41972293","title":"Dynamic S-Acylation of GSDMA Regulates Pyroptosis.","date":"2026","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/41972293","citation_count":0,"is_preprint":false},{"pmid":"41279037","id":"PMC_41279037","title":"Dynamic S-acylation of GSDMA regulates pyroptosis.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41279037","citation_count":0,"is_preprint":false},{"pmid":"42012959","id":"PMC_42012959","title":"Cell-type-resolved transcriptomic landscape of human focal cortical dysplasia.","date":"2026","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/42012959","citation_count":0,"is_preprint":false},{"pmid":"42107007","id":"PMC_42107007","title":"S-palmitoylation of ATG4B facilitates the deconjugation of LC3-II to promote autophagy.","date":"2026","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/42107007","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.16.682910","title":"Dynamic  <i>S</i>  -acylation of GSDMA regulates pyroptosis","date":"2025-10-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.16.682910","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":15206,"output_tokens":3833,"usd":0.051556,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11422,"output_tokens":4543,"usd":0.085343,"stage2_stop_reason":"end_turn"},"total_usd":0.136899,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2015,\n      \"finding\": \"ABHD17 proteins (including ABHD17A) function as novel protein depalmitoylases that accelerate palmitate turnover on N-Ras and PSD-95. ABHD17A catalytic activity is required for N-Ras depalmitoylation and re-localization from the plasma membrane to internal cellular membranes. APT1/APT2 inhibition did not affect N-Ras or PSD-95 palmitate turnover, establishing ABHD17 enzymes as distinct, non-redundant depalmitoylases identified via activity-based profiling of serine hydrolases.\",\n      \"method\": \"Dual pulse-chase comparing palmitate and protein half-lives; activity-based protein profiling; shRNA knockdown; small-molecule inhibition (Palmostatin B); subcellular localization imaging\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (pulse-chase, activity profiling, KD, inhibitor, localization), replicated across substrates, foundational study\",\n      \"pmids\": [\"26701913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ABHD17A, ABHD17B, and ABHD17C are the physiological depalmitoylating enzymes for PSD-95 in neurons. ABHD17A localizes to recycling endosomes, the dendritic plasma membrane, and the synaptic fraction. Expression of ABHD17 in neurons selectively reduced PSD-95 palmitoylation and synaptic clustering of PSD-95 and AMPA receptors. Inhibition of ABHD17 expression dramatically delayed the kinetics of PSD-95 depalmitoylation as quantified by the APEGS method.\",\n      \"method\": \"Heterologous cell depalmitoylation assay; APEGS quantitative palmitoylation assay; neuronal expression/knockdown; immunofluorescence localization; synaptic fractionation\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (biochemical assay, quantitative APEGS, KD, localization, functional synaptic readout) in a single rigorous study\",\n      \"pmids\": [\"27307232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ABHD17A-C depalmitoylating enzymes control dynamic palmitoylation of MAP6/STOP protein, regulating its shuttling between membranes and microtubules and its retention in axons. ABHD17-mediated depalmitoylation is required for MAP6-dependent microtubule stabilization and axon maturation.\",\n      \"method\": \"Live imaging; neuronal KD/OE; palmitoylation biochemical assays; axonal localization experiments\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct loss-of-function with defined cellular phenotype (axon maturation, MAP6 localization), single lab, multiple methods\",\n      \"pmids\": [\"28521134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ABHD17A acts as a depalmitoylase for TEAD transcription factors, contributing to TEAD destabilization and proteasomal degradation via E3 ubiquitin ligase CHIP when TEAD is depalmitoylated. TEAD depalmitoylation by ABHD17A (and APT2) is regulated by cell density in a Nf2/Merlin-dependent manner.\",\n      \"method\": \"Overexpression of ABHD17A; palmitoylation assays; cell density manipulation; proteasome inhibitor treatment; Nf2/Merlin knockdown\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional assays with defined molecular outcome (TEAD depalmitoylation, degradation), single lab, multiple methods\",\n      \"pmids\": [\"31043565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ABHD17A deacylates the stress-regulated exon (STREX) domain of BK channels in a site-specific manner, inhibiting channel activity without affecting surface expression. ABHD17A has no effect on the S0-S1 domain of BK channels (which is deacylated by Lypla1), demonstrating that distinct S-acylated domains within the same polytopic transmembrane protein are regulated by different acyl protein thioesterases.\",\n      \"method\": \"Overexpression and knockdown of ABHD17A; acyl-biotin exchange assay; electrophysiology; surface biotinylation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional assay (electrophysiology + biochemical deacylation), site-specificity shown, single lab\",\n      \"pmids\": [\"32913120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ABHD17A depalmitoylates the divergent C-terminal tail of CNAβ1 (a calcineurin isoform), reversing its palmitoylation-dependent plasma membrane and Golgi localization and thereby altering its substrate specificity and function at the PI4KA complex.\",\n      \"method\": \"Depalmitoylase overexpression; palmitoylation assays; subcellular localization imaging; hydrogen-deuterium exchange MS; substrate identification\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization and palmitoylation assays with functional consequence, multiple methods, single lab\",\n      \"pmids\": [\"34663815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ABHD17A depalmitoylates NLRP3 at the LRR domain, counteracting ZDHHC5-mediated NLRP3 palmitoylation. A Crohn's disease-associated NLRP3 mutation was found to be associated with defective ABHD17A binding and hyper-palmitoylation, linking ABHD17A to inflammasome regulation.\",\n      \"method\": \"Silencing and overexpression; palmitoylation assays; co-immunoprecipitation; NLRP3 inflammasome activation assays (caspase-1, IL-1β, GSDMD); site-directed mutagenesis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Co-IP, palmitoylation assay, functional inflammasome readouts, mutagenesis, in vivo mouse data), single rigorous study\",\n      \"pmids\": [\"38092000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ABHD17A is the depalmitoylating enzyme for Rap2b in colorectal cancer cells, removing palmitate from C176/C177, causing Rap2b relocation from the plasma membrane to the cytosol and inhibiting cell migration and invasion. PI3K signaling phosphorylates ABHD17A to modulate its depalmitoylase activity on Rap2b.\",\n      \"method\": \"ABHD17A overexpression/KD; palmitoylation assays; subcellular fractionation/localization; migration/invasion assays; pharmacological PI3K inhibition\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct depalmitoylation and localization assays with functional cell migration readout, single lab, multiple methods\",\n      \"pmids\": [\"39277583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ABHD17A depalmitoylates SCAP, antagonizing ZDHHC3-mediated SCAP S-acylation at C264 and thereby modulating SCAP ubiquitination and cholesterol biosynthesis in hepatocellular carcinoma cells.\",\n      \"method\": \"Overexpression/KD; palmitoylation assays; ubiquitination assays; cholesterol biosynthesis measurement\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct depalmitoylation assay with defined functional output (SCAP ubiquitination, cholesterol), single lab, multiple methods\",\n      \"pmids\": [\"39522165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ABHD17A (and ABHD17B, ABHD17C) are the acyl protein thioesterases responsible for NOD2 deacylation. Inhibiting ABHD17 increased plasma membrane localization of NOD2 and enhanced NOD2-dependent NF-κB activation and pro-inflammatory cytokine production, including for Crohn's disease-associated poorly-acylated NOD2 variants.\",\n      \"method\": \"RNA interference; small-molecule ABHD17 inhibitors; acyl-resin-assisted capture; confocal microscopy; immunoblotting; cytokine multiplex assays\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (RNAi, inhibitors, biochemical acylation capture, imaging, functional NF-κB/cytokine readout), single lab\",\n      \"pmids\": [\"40054525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ABHD17A physically interacts with IFITM1 and, unexpectedly, increases IFITM1 S-palmitoylation (rather than removing it) by downregulating the depalmitoylase ABHD16A. This indirect mechanism counteracts ABHD16A-catalyzed palmitate removal from IFITM1, thereby enhancing IFITM1's antiviral activity.\",\n      \"method\": \"Co-immunoprecipitation; palmitoylation assays; overexpression/KD of ABHD17A and ABHD16A; antiviral functional assays\",\n      \"journal\": \"Biomolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus palmitoylation biochemistry and functional antiviral readout, single lab, multiple methods\",\n      \"pmids\": [\"40723864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ABHD17A's plasma membrane targeting and catalytic activity are governed by a palmitoylation code in its conserved N-terminal cysteine cluster (C10, C11, C14, C15, C18). Modifications at the middle region (C14, C15) are critical for PM targeting and catalytic activity, while front (C10, C11) and rear (C18) modifications influence endosomal routing. YXXØ-dependent endosomal sorting (disruption of L115A proximal motif) redirects ABHD17A to autophagosomes and decreases surface abundance. This palmitoylation code mechanism is conserved in ABHD17B and ABHD17C.\",\n      \"method\": \"Alanine scanning mutagenesis; confocal microscopy; biochemical acylation assays; ABHD17A substrate depalmitoylation assays\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis, imaging, and biochemical assays establishing mechanism, single lab, single study\",\n      \"pmids\": [\"41155484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ABHD17A is identified as one of the deacylating enzymes regulating the dynamic fatty acylation cycle of GSDMA, controlling GSDMA-mediated pyroptosis.\",\n      \"method\": \"Identification via biochemical deacylation assay; functional pyroptosis readout\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single study, limited mechanistic detail in abstract about specific method used for ABHD17A's role\",\n      \"pmids\": [\"41972293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"ABHD17A depalmitoylates METTL3 at cysteine 376, reversing ZDHHC24-mediated palmitoylation. This depalmitoylation disrupts METTL3 condensate formation near ribosomes and promotes chaperone-mediated autophagy of METTL3, reducing its stability. A small molecule (Isoborneol) that disrupts METTL3–ABHD17A interaction enhances METTL3 palmitoylation and alleviates osteoarthritis in vivo.\",\n      \"method\": \"Palmitoylation assays; co-immunoprecipitation; condensate imaging; KO/OE in cells and mice; OA mouse models; AI-guided small-molecule screening\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct depalmitoylation assay, Co-IP, in vivo phenotype, multiple methods; single lab\",\n      \"pmids\": [\"41719123\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ABHD17A is a membrane-anchored serine hydrolase/depalmitoylase that removes S-palmitoyl modifications from a growing list of substrates—including N-Ras, PSD-95, MAP6, TEAD, BK channels, CNAβ1, NLRP3, Rap2b, SCAP, NOD2, GSDMA, and METTL3—regulating their membrane association, subcellular localization, protein–protein interactions, and downstream signaling; ABHD17A's own depalmitoylase activity and plasma membrane targeting are controlled by a palmitoylation code in its N-terminal cysteine cluster and by YXXØ-dependent endosomal sorting, and it can also indirectly increase substrate palmitoylation by downregulating competing depalmitoylases such as ABHD16A.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ABHD17A is a membrane-anchored serine hydrolase that acts as a protein depalmitoylase, accelerating the turnover of S-palmitoyl modifications on substrate proteins and thereby controlling their membrane association, subcellular localization, and downstream signaling [#0]. It was identified by activity-based serine-hydrolase profiling as a non-redundant depalmitoylase—distinct from APT1/APT2—that drives palmitate turnover on N-Ras and PSD-95, with its catalytic activity required to relocate N-Ras from the plasma membrane to internal membranes [#0]; in neurons it depalmitoylates PSD-95 from recycling endosomes and the synaptic compartment to regulate synaptic PSD-95 and AMPA receptor clustering [#1]. Its substrate range is broad, spanning cytoskeletal and signaling proteins such as MAP6 in axon maturation [#2], TEAD transcription factors whose depalmitoylation promotes CHIP-mediated degradation in a density/Nf2-dependent manner [#3], site-specific deacylation of the BK channel STREX domain [#4], and CNAβ1 calcineurin [#5]. A recurring theme is direct antagonism of ZDHHC palmitoyltransferases at defined cysteines: ABHD17A counters ZDHHC5 on NLRP3, ZDHHC3 on SCAP, and ZDHHC24 on METTL3, thereby tuning inflammasome activity [#6], cholesterol biosynthesis [#8], and METTL3 condensate formation and stability [#13]. Through these activities it modulates innate immune signaling—NLRP3 and NOD2 deacylation linking it to Crohn's disease-associated variants [#6, #9]—as well as cancer cell migration via Rap2b [#7]. ABHD17A's own plasma-membrane targeting and catalytic activity are governed by a palmitoylation code in its N-terminal cysteine cluster and by YXXØ-dependent endosomal sorting [#11], and it can paradoxically raise substrate palmitoylation indirectly by downregulating the competing depalmitoylase ABHD16A [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 2015,\n      \"claim\": \"Established that ABHD17 enzymes are a previously unrecognized class of protein depalmitoylase, resolving how palmitate turnover proceeds on N-Ras and PSD-95 independently of APT1/APT2.\",\n      \"evidence\": \"Dual pulse-chase of palmitate vs protein half-life, activity-based protein profiling, shRNA knockdown, Palmostatin B inhibition and localization imaging\",\n      \"pmids\": [\"26701913\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic mechanism and structural basis of substrate selection not defined\", \"Endogenous substrate repertoire beyond N-Ras/PSD-95 unknown at this stage\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed ABHD17A is a physiological PSD-95 depalmitoylase in neurons, linking its activity to synaptic receptor clustering and defining its endosomal/synaptic localization.\",\n      \"evidence\": \"Heterologous depalmitoylation assay, quantitative APEGS palmitoylation measurement, neuronal expression/knockdown, immunofluorescence and synaptic fractionation\",\n      \"pmids\": [\"27307232\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of ABHD17A vs ABHD17B/C in vivo not separated\", \"Mechanism targeting the enzyme to recycling endosomes not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Extended substrate scope to cytoskeleton-associated MAP6, connecting depalmitoylation to microtubule stabilization and axon maturation.\",\n      \"evidence\": \"Live imaging, neuronal knockdown/overexpression, palmitoylation biochemistry, axonal localization assays\",\n      \"pmids\": [\"28521134\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct enzyme-substrate interaction not biochemically isolated\", \"ABHD17 isoform-specific roles not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected ABHD17A depalmitoylation to transcription-factor turnover, showing TEAD depalmitoylation routes it to CHIP-mediated proteasomal degradation under density/Nf2 control.\",\n      \"evidence\": \"ABHD17A overexpression, palmitoylation assays, cell-density manipulation, proteasome inhibition, Nf2/Merlin knockdown\",\n      \"pmids\": [\"31043565\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous ABHD17A loss-of-function effect on TEAD not established\", \"Shared role with APT2 not deconvolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated site-specificity by showing ABHD17A deacylates only the STREX domain of BK channels (not S0-S1), establishing that distinct acylated domains of one protein are served by different thioesterases.\",\n      \"evidence\": \"Overexpression/knockdown, acyl-biotin exchange, electrophysiology, surface biotinylation\",\n      \"pmids\": [\"32913120\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis for domain selectivity unknown\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed ABHD17A depalmitoylates CNAβ1 calcineurin to reverse its membrane/Golgi localization and alter its substrate specificity.\",\n      \"evidence\": \"Depalmitoylase overexpression, palmitoylation assays, localization imaging, HDX-MS substrate analysis\",\n      \"pmids\": [\"34663815\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological setting and endogenous regulation not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined ABHD17A as a direct ZDHHC5 antagonist on NLRP3 and tied it to inflammasome control and a Crohn's disease-associated NLRP3 variant with defective ABHD17A binding.\",\n      \"evidence\": \"Silencing/overexpression, palmitoylation assays, co-immunoprecipitation, inflammasome readouts (caspase-1, IL-1β, GSDMD), mutagenesis, in vivo mouse data\",\n      \"pmids\": [\"38092000\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of NLRP3-ABHD17A binding interface not mapped\", \"Causal disease contribution beyond association not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified ABHD17A as the Rap2b depalmitoylase regulated by PI3K-mediated phosphorylation, linking its activity to colorectal cancer cell migration and invasion.\",\n      \"evidence\": \"Overexpression/knockdown, palmitoylation assays, fractionation/localization, migration/invasion assays, PI3K inhibition\",\n      \"pmids\": [\"39277583\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphosite(s) on ABHD17A controlling activity not mapped\", \"In vivo tumor relevance not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed ABHD17A antagonizes ZDHHC3 acylation of SCAP at C264 to modulate SCAP ubiquitination and cholesterol biosynthesis.\",\n      \"evidence\": \"Overexpression/knockdown, palmitoylation assays, ubiquitination assays, cholesterol measurement in hepatocellular carcinoma cells\",\n      \"pmids\": [\"39522165\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect effect on SCAP ubiquitination not fully separated\", \"Single-lab, single-cell-context finding\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established ABHD17 enzymes as the NOD2 deacylases controlling its membrane localization and NF-κB output, including for Crohn's-associated poorly-acylated variants.\",\n      \"evidence\": \"RNAi, small-molecule ABHD17 inhibitors, acyl-resin-assisted capture, confocal microscopy, cytokine multiplex assays\",\n      \"pmids\": [\"40054525\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"ABHD17A-specific contribution vs ABHD17B/C not isolated\", \"Direct NOD2 binding not demonstrated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealed an indirect, non-catalytic mode in which ABHD17A increases IFITM1 palmitoylation by downregulating the competing depalmitoylase ABHD16A, enhancing antiviral activity.\",\n      \"evidence\": \"Co-immunoprecipitation, palmitoylation assays, overexpression/knockdown of ABHD17A and ABHD16A, antiviral functional assays\",\n      \"pmids\": [\"40723864\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which ABHD17A downregulates ABHD16A unknown\", \"Direct vs indirect IFITM1 effect not fully resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined the regulatory logic of ABHD17A itself: an N-terminal cysteine palmitoylation code and YXXØ endosomal sorting motif govern its PM targeting, catalytic activity, and trafficking.\",\n      \"evidence\": \"Alanine-scanning mutagenesis, confocal microscopy, acylation assays, substrate depalmitoylation assays\",\n      \"pmids\": [\"41155484\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enzymes writing/erasing the ABHD17A code not identified\", \"Dynamics of the code under physiological signaling unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Implicated ABHD17A among the deacylases regulating GSDMA fatty-acylation cycling and pyroptosis.\",\n      \"evidence\": \"Biochemical deacylation assay and pyroptosis functional readout\",\n      \"pmids\": [\"41972293\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Limited mechanistic detail on ABHD17A's specific role\", \"ABHD17A-specific loss-of-function not isolated\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Showed ABHD17A depalmitoylates METTL3 at C376 to disrupt its condensates and promote chaperone-mediated autophagy, with a small molecule blocking the interaction alleviating osteoarthritis.\",\n      \"evidence\": \"Palmitoylation assays, co-IP, condensate imaging, KO/OE in cells and mice, OA models, AI-guided small-molecule screening\",\n      \"pmids\": [\"41719123\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of METTL3-ABHD17A binding not defined\", \"Generalizability beyond osteoarthritis context unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ABHD17A achieves its broad yet site-specific substrate selectivity, and how its activity is dynamically regulated across tissues by phosphorylation and its own palmitoylation code, remains unresolved.\",\n      \"evidence\": \"No structural or systematic substrate-determinant study present in the corpus\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structure of ABHD17A or enzyme-substrate complex\", \"Determinants distinguishing direct depalmitoylation from indirect ABHD16A-mediated effects not generalized\", \"Isoform-specific (A vs B vs C) division of labor not systematically defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 4, 6, 7, 8, 13]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 11]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [1, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 1, 6, 8, 13]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 9]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"NLRP3\", \"NOD2\", \"Rap2b\", \"SCAP\", \"TEAD\", \"METTL3\", \"IFITM1\", \"ABHD16A\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}